Madrigal Pharmaceuticals, Inc. (MDGL) Key Statistics & Metrics

Madrigal Pharmaceuticals, Inc. (MDGL) has an ST Score of 51.6 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Wall Street's consensus rating on MDGL is Buy based on 25 analyst ratings. Our own ST Score grades it C+ (51.6/100). This is data, not investment advice — always do your own research.

Madrigal Pharmaceuticals, Inc. (MDGL) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Madrigal Pharmaceuticals, Inc. (MDGL) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Madrigal Pharmaceuticals, Inc. (MDGL) earns a profitability grade of B-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Madrigal Pharmaceuticals, Inc. (MDGL) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Madrigal Pharmaceuticals, Inc. (MDGL) is $677.00 from 25 analysts, which is +0.3% versus the recent price of $531.52.

Madrigal Pharmaceuticals, Inc. (MDGL) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.